I continue to hold about 125,000 shares, not because of the lupus drug, but simply because of the cash on hand and most importantly, the 275 million in net operating losses. B-mod is a long shot and one of the reasons there is no partner is because the lupus market is tiny and there are major competitors in phase 3, with similar b-cell target.
I think the company will be sold. I am only bashing posters that are continually claiming the data is strong. The data sucked. If it was good, the stock would not have fallen 80% the day it was released. Anyone that cannot recognize that is delusional. So why are these specialty hedge funds buying shares now? Probably the same reason I am, the downside is limited due to the cash and NOLs.
The CASH and NOLs of a drug company with no drug-success prospects are largely irrelevant. Why? Well, the company will continue to burn cash without any success, and NOLs won't play any part until the company makes a profit (which a company with no drug-success prospects never will).
The point: The big guys (if at all) are NOT buying into ANTH for its cash and NOLs. They are buying in because they see what your pea-sized brain cannot possibly see (how can your brain see, when you don't even know what 'statistical significance' means).
Why would the company be sold now, right after a secondary and before initiation of a phase 3 trial? And you're holding all these shares of a company with a drug you believe is dead on that hope? Give me a break, man